These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 19305378)

  • 21. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C; Einstein M; Lucey MR; Said A
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatorenal syndrome.
    Cárdenas A; Gines P
    Clin Liver Dis; 2006 May; 10(2):371-85, ix-x. PubMed ID: 16971267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R; Lebrec D
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatorenal syndrome: a critical update.
    Wadei HM
    Semin Respir Crit Care Med; 2012 Feb; 33(1):55-69. PubMed ID: 22447261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: a retrospective analysis.
    Appenrodt B; Zielinski J; Brensing KA; Heller J; Sauerbruch T; Schepke M
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1428-32. PubMed ID: 19794309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of hepatorenal syndrome.
    McCormick PA; Donnelly C
    Pharmacol Ther; 2008 Jul; 119(1):1-6. PubMed ID: 18539334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: hepatorenal syndrome--how to assess response to treatment and nonpharmacological therapy.
    Arroyo V
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():49-54; discussion 55-6. PubMed ID: 15335402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the management of hepato-renal syndrome.
    Hasper D; Jörres A
    Liver Int; 2011 Sep; 31 Suppl 3():27-30. PubMed ID: 21824281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies.
    Meltzer J; Brentjens TE
    Curr Opin Anaesthesiol; 2010 Apr; 23(2):139-44. PubMed ID: 20124895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment].
    Torre A; Terra C; Guevara M; Ginès P
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():8-14. PubMed ID: 15195529
    [No Abstract]   [Full Text] [Related]  

  • 32. The hepatorenal syndrome.
    Munoz SJ
    Med Clin North Am; 2008 Jul; 92(4):813-37, viii-ix. PubMed ID: 18570944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of hepatorenal syndrome].
    Walter E
    Praxis (Bern 1994); 1997 Jan; 86(4):102-3. PubMed ID: 9064719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis.
    Angeli P; Merkel C
    J Hepatol; 2008; 48 Suppl 1():S93-103. PubMed ID: 18304678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatorenal syndrome: a dreaded complication of end-stage liver disease.
    Cárdenas A
    Am J Gastroenterol; 2005 Feb; 100(2):460-7. PubMed ID: 15667508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatorenal syndrome].
    Pŭrvanov P
    Khirurgiia (Sofiia); 2002; 58(2):34-9. PubMed ID: 12515019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The therapy of the hepatorenal syndrome in liver cirrhosis].
    Biecker E; Brensing KA; Perz J; Woitas R; Sauerbruch T
    Dtsch Med Wochenschr; 1999 Sep; 124(36):1039-42. PubMed ID: 10506842
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatorenal syndrome: pathophysiology and management.
    Wadei HM; Mai ML; Ahsan N; Gonwa TA
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1066-79. PubMed ID: 17699328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.